Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Batten disease (also known as neuronal ceroid lipofuscinoses) constitutes a family of
devastating lysosomal storage disorders that collectively represent the most common …

The human σ1 receptor is an enigmatic endoplasmic-reticulum-resident transmembrane
protein implicated in a variety of disorders including depression, drug addiction, and …

The σ 1 and σ 2 receptors are enigmatic proteins that have attracted attention for decades
due to the chemical diversity and therapeutic potential of their ligands. However, despite …

Currently, there are no effective therapies to ameliorate the pathological progression of
Alzheimer's disease (AD). Evidence suggests that environmental factors may contribute to …

Methamphetamine (METH) is a highly addictive psychostimulant and one of the most widely
abused drugs worldwide. The continuous use of METH eventually leads to drug addiction …

Dextromethorphan (DM) has been used for more than 50 years as an over-the-counter
antitussive. Studies have revealed a complex pharmacology of DM with mechanisms …

Cell stress and impaired oxidative phosphorylation are central to mechanisms of synaptic
loss and neurodegeneration in the cellular pathology of Alzheimer's disease (AD). In this …

The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly
gaining interest in neuroscience research. Much of this interest stems from recent clinical …

Alzheimer's disease (AD) is one of the most common forms of dementia among elder
people, which is a progressive neurodegenerative disease that results from a chronic loss of …